PBAC's latest decision on Pneumococcal polysaccharide conjugate 13-valent: Recommended with restriction (2018). Considered for Active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in infants and children.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2018
Submissions
1
2018 → 2018
Eligible population
Infants and children in Australia aged 2 months and above, with differentiated schedules for Aboriginal and Torres Strait Islander children in at-risk areas and children with underlying medical conditions.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
Registry
Primary endpoint
IPD reduction
Comparator
current 3+0 schedule
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; change proposed to be cost-neutral to the NIP.